Search

Search
Generic filters

Formulation of Medicated Chewing Gum: Excipient Handling Procedure to Prevent Problems

Medicated Chewing Gum Excipient

Chewing gum is popular among consumers, being enjoyed by people of all ages. The first successful formulation of medicated chewing gum products was in the early 1970s when Nicorette was launched by Pfizer for use in smoking cessation.

Since then, directly compressible chewing gum has quickly gained momentum as a readily adaptable platform for delivery pharmaceutical and nutracetical actives. it is currently recognized as a dosage form and defined in pharmacopoeias, including the European Pharmacopoeia.

Aside from their reported health benefits, such as helping boost blood flow to the brain and strengthening tooth enamel, chewing gums offer the following advantages to the pharmaceutical product formulator:

  • Chewing gum can help increase patient adherence
  • It offers fast onset of action and can improve bioavailability of drugs as some amount of drug is absorbed through the buccal mucosa
  • It can also be administered discretely and without the need for water.

Although directly compressed gum excipient systems are widely promoted as relatively trouble-free and amenable on standard tableting equipment, product developers often experience several technical challenges during formulation and evaluation of medicated chewing gum products. This Technical Note provides a quick reference guide on how to handle and trouble-shoot common issues when using this material.

Types of Medicated Chewing Gum and Manufacturing Methods

There are currently two types of medicated chewing gum and manufacturing methods, namely extruded gum and compressed gum.

Extruded gums are produced using a traditional method of manufacture whereby the ingredients are intensively mixed at elevated temperature to produce a matrix. The matrix is then cut into ‘pillows’ and subsequently sprayed with coating agents.

Compressed gums are manufactured by blending active ingredients with the gum base and compressing the obtained mix on a tableting press. The direct compression method is a cool and dry process suitable for a wide range of ingredients. An example of a compressed gum system is the Health in Gum® excipient by CAFOSA SA, part of the MARS WRIGLEY conglomerate.

The Health in Gum® excipient system, the focus of this Technical Note, utilizes a food-grade gum base, polyols, plasticizers and anticaking agents. The active ingredient(s), sweeteners and flavours are added to the base, blended and compressed on standard tableting equipment. Additional processing or adaptations of equipment is not required.

Recommended Procedure for Handling Health in Gum®

  1. Break the lumps, if any, with a vibrating sieve (1 mm). Remove any pieces that you cannot break manually.
  2. In the selected blender, add the powder gum, the active and any other ingredient in powder form (e.g flavour in powder form, intensive sweeteners and colours) following the suggested formulation. Mixing time will depend on the type of mixer and the batch size. Gentle mixing needs more time but it tends to be better than intensive mixing.
  3. Add the liquid flavour so that it distributes homogeneously into the blend (for instance, spraying). If you cannot add the liquid to the mixer, you need to make a premix of the flavour and some of the silicon dioxide.
  4. After spraying, add between 0.5% of Silicon Dioxide with high oil absorption capacity (for instance, Sipernat 50S from Evonik or Syloid 244FP from Grace) and mix until you get a dry and free flowing.
  5. Add lubricant (2% on the case of Magnesium stearate) into the blender and mix until homogeneous.
  6. Sieve again, as some ingredients may agglomerate (liquid flavour and silicon dioxide).
  7. Before adding the final mix to the pressing machine, add a small quantity of the selected lubricant to the tablet press and run the machine slowly for a few minutes to allow the lubricant to cover punches. This will reduce the initial stickiness.
  8. Start compressing. Standard speeds are between 30k and 40k tablets/hr. Adjust pressure and weight, with final tablet hardness between 7 and 10 mm.

Tips and Suggestions

  1. Add silicon dioxide before adding the liquid flavour. The total silica content should however not exceed 2% to give the chewing gum the optimum texture.
  2. The liquid flavour should have Triacetin or a suitable oil (e.g Vitamine E) as the solvent to be chewing gum compatible
  3. Ensure that the product does not exceed 27ºC during processing. Heating up leads to a loss of fluidity and increases stickiness.
  4. Experiment with compression forces as they have different effects on gum texture depending on the formulation ingredients.
  5. Some ingredients with acid properties may affect to the texture of the gum. In this case, we suggest changing metallic stearates by stearic acid.
  6. Gums should be stored away from excessive heat, in a dry cool area. Keep away from direct light. The optimum conditions: 20ºC – 50% RH.

Suggested starting formula

Here is a simple formula to get you started:

Directly compressible medicated chewing gum starter formula

Touble Shooting Guide

Medicated Chewing Gum Trouble Shooting Guide

Directly Compressible Chewing Gum – Common Problems and Potential Solutions Infographic

 

 

Thinking impaired in 60% of COVID-19 survivors

In a sample of over 400 older adults in Argentina who had recovered from COVID-19, more than 60% displayed some degree of cognitive impairment, a researcher from The University of Texas Health Science Center at San Antonio reported July 29 at the Alzheimer’s Association International Conference.
GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab

GSK and Vir Biotechnology announce Joint Procurement Agreement with European Commission for COVID-19 treatment, sotrovimab

GlaxoSmithKline plc and Vir Biotechnology, Inc. announced they have signed a Joint Procurement Agreement with the European Commission to supply up to 220,000 doses of sotrovimab, an investigational single dose SARS-CoV-2 monoclonal antibody for the treatment of adults and adolescents (aged 12 years and over and weighing at least 40 kg) with COVID-19 who do not require oxygen supplementation and who are at risk of progressing to severe COVID-19.
FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

FDA approves first interchangeable biosimilar insulin product for treatment of diabetes

The U.S. Food and Drug Administration approved the first interchangeable biosimilar insulin product, indicated to improve glycemic control in adults and pediatric patients with Type 1 diabetes mellitus and in adults with Type 2 diabetes mellitus. Semglee (insulin glargine-yfgn) is both biosimilar to, and interchangeable with (can be substituted for), its reference product Lantus (insulin glargine), a long-acting insulin analog.
Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine

Pfizer and BioNTech to provide U.S. government with an additional 200 million doses of COVID-19 vaccine

Pfizer Inc. (NYSE: PFE) and BioNTech SE (Nasdaq: BNTX) announced that the U.S. government has purchased an additional 200 million doses of the Pfizer-BioNTech COVID-19 Vaccine. These doses are expected to be delivered from October 2021 through April 2022. This brings the total number of doses to be supplied by the companies to the U.S. government under its existing supply agreement to 500 million.
Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people

Vaxzevria and mRNA COVID-19 vaccines showed similar and favourable safety profiles in a population-based cohort study of over a million people

In a large real-world study, data published as a pre-print on The Lancet server from over one million individuals assessed the incidence rates of blood clotting disorders of thromboembolism and thrombocytopenia, including the very rare thrombosis with thrombocytopenia (TTS) following vaccination with an mRNA vaccine or Vaxzevria, and compared them with expected rates in a general population and in people with COVID-19.

Advantages of intranasal vaccination against SARS-CoV-2

There are many reasons that an intranasal vaccine against the SARS-CoV-2 virus would be helpful in the fight against COVID-19 infections, University of Alabama at Birmingham immunologists Fran Lund, Ph.D., and Troy Randall, Ph.D., write in a viewpoint article in the journal Science.

Antibiotics may help to treat melanoma

Some antibiotics appear to be effective against a form of skin cancer known as melanoma. Researchers at KU Leuven, Belgium, examined the effect of these antibiotics on patient-derived tumours in mice. Their findings were published in the Journal of Experimental Medicine.
Back to Top
Product has been added to your cart